Ab-CPP-MSP-siRNA (cetuximab–PEG–LMWP–GGPLGVR–siRNA; ARC)
Sequence: VSRRRRGGRRRRRRGGPLGVR
| Experiment Id | EXP001826 |
|---|---|
| Paper | Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker me |
| Peptide | Ab-CPP-MSP-siRNA (cetuximab–PEG–LMWP–GGPLGVR–siRNA; ARC) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | Not consistently stated for uptake; silencing assays used 100 nM. |
| Mixing Ratio | Covalent ARC. |
| Formulation Format | Antibody–multifunctional peptide–siRNA covalent conjugate (ARC) |
| Formulation Components | Cetuximab linked to PEG–LMWP–GGPLGVR–siRNA. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Uptake studies: HCT116 (EGFR+), HT1080 (EGFR+), SW620 (EGFR low) with confocal microscopy |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro uptake/activation (confocal; Ab/siRNA separation after substrate cleavage) |
| Output Value | Strong intracellular siRNA signal in HCT116 and HT1080; weak in SW620 (controls). |
| Output Units | |
| Output Notes | Activation depends on MMP-2 cleavage; no separate functional knockdown reported specifically for MSP construct in main text. |
| Toxicity Notes | |
| Curation Notes |